BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Files An 8-K Other Events
Item8.01. Other Events.
On March 9, 2017, the Company entered into an underwriting
agreement (the Underwriting Agreement) with J. P. Morgan
Securities LLC, as representative of the underwriters named in
Schedule 1 thereto (the Underwriters), with respect to the
issuance and sale in an underwritten public offering (the
Offering) by the Company of 5,294,118 shares of the Companys
common stock at a price to the public of $8.50 per share. to the
Underwriting Agreement, the Company also granted the underwriters
a 30-day option (the Underwriters Option) to purchase up to an
additional 794,117 shares of the Companys common stock. On March
10, 2017, the Underwriters exercised the Underwriters Option to
purchase 766,997 shares.
The shares issuable in the Offering, including to the
Underwriters Option, have been registered under the Securities
Act of 1933 (the Securities Act) to a registration statement on
Form S-3 (Registration No. 333-202466) of the Company (the
Registration Statement), and a prospectus supplement dated March
9, 2017, filed with the Securities and Exchange Commission to
Rule 424(b) of the Securities Act on March 10, 2017. The closing
of the Offering, including the shares issuable to the partial
exercise of the Underwriters Option, is expected to occur on
March 15, 2017. The legal opinion of Gibson, Dunn Crutcher LLP
relating to the Registration Statement is filed herewith as
Exhibit 5.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 1.1 |
Underwriting Agreement, dated March 9, 2017, by and between |
|
| 5.1 | Opinion of Gibson, Dunn Crutcher LLP. |
About BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine. Its product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza, in the United States as RAPIVAB. RAPIVAB is used for the treatment of acute uncomplicated influenza. Its BCX4430 is a broad-spectrum antiviral (BSAV) research program. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Recent Trading Information
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) closed its last trading session down -0.24 at 8.36 with 1,480,407 shares trading hands.